Stock TRML TOURMALINE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
16.96 USD +2.17% Intraday chart for Tourmaline Bio, Inc. +21.75% -35.22%
May. 16 Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial CI
May. 13 Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
GL
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
GL
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GL
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
GL
Tourmaline Bio Announces Proposed Public Offering of Common Stock
GL
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
GL
Tourmaline Bio added to the NASDAQ Biotechnology Index
GL
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
GL
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
AQ
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
AQ
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
AQ
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
BU
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
BU
TALARIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
TALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to Shareholders
BU
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
AQ
Talaris Therapeutics Announces Leadership Transition
AQ
Talaris Therapeutics : Costs Associated with Exit/Disposal - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRML Stock
  4. News Tourmaline Bio, Inc.
  5. Press Releases